Klin Farmakol Farm. 2005;19(4):225-228

Combined oral contraceptive drugs with positive influence on skin complexion and function from dermatological viewpoint

Jarmila Rulcová
Dermatovenerologická klinika, FN Brno

Acne vulgaris combined usually with seborrhoea and in some persons with signs of hyperandrogenaemia ranks among the most common conditions in adolescents. In spite of the fact that in females suffering from acne, hyperseborrhoea, and mild forms of hirsutism serum androgen levels are usually not elevated, treatment with combined contraceptive drugs is mostly effective. Drugs contaning anti-androgenic components are the most suitable ones due to the blocking effect on the receptor level for androgens. The activity of the enzyme 5 alpha-reductase is markedly diminished. The most considerable anti-androgenic activity was observed in cyproteronacetate, followed by chlormadinon, dienogest, and drospirenone. Indication of only several combined contraceptive drugs has been approved directly for treatment of acne vulgaris and seborrhoea. The best suitable contraceptive combination contains 35 µg of ethinylestradiol and 2 mg of cyproteronacetate. This combination is the most effective and commonly used one in dermatology (Diane® 35).

Keywords: Key words: androgen-dependent diseases, androgens, anti-androgens, combined hormonal contraceptive drugs, positive effect on complexion state

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rulcová J. Combined oral contraceptive drugs with positive influence on skin complexion and function from dermatological viewpoint. Klin Farmakol Farm. 2005;19(4):225-228.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Seidlová D. Kontracepce pro praxi, Praha: Maxdorf s. r. o. 1997: 40-81.
    2. Vollmer H. Hormony a co o nich musí vědět ženy (z německého originálu přeložila Dušková J.). Praha: Pragma 1999: 56-84.
    3. Čepický P. Úvod do antikoncepce pro lékaře negynekology. Praha: LEVRET s. r. o. 2002: 61-84.
    4. Schmidt JB. Dermatological aspects of hirsutism. In: Spona J, Aydinlik S. Hirsutism and endocrine Dermatological problems. The Parthenon Publishing Group Ltd., New Jersey, U. S. A., 1989: 21-27.
    5. Rulcová J. Role hormonů u nemocných s acne vulgaris. Slovenský LEKÁR, 2000; 5-6: 209-211.
    6. Nürnberger F. Clinical studies with Diane(R) 35 versus Diane(R). In Nürnberger, F. The Therapy of Acne vulgaris in Women. Walter de Gruyter et Co., Berlin - New York, 1990: 31-36. Go to original source...
    7. Cibula D. Hormonální kontracepce. V: Cibula D, Henzl MR, Živný J, a kol. Základy gynekologické endokrinologie. Grada Publishing, spol. s r. o., Praha 2002: 201-226.
    8. Plewig G, Kligman AM. Acne and Rosacea. 3 rd Completely Revised and Enlarged Edition. Springer-Verlag Berlin Heidelberg New York, 2000: 96-98. Go to original source...
    9. Stárka L. Androgeny. V: Cibula D, Henzl MR, Živný J, a kol. Základy gynekologické endokrinologie. Grada Publishing, spol. s r. o., Praha, 2000: 49-64.
    10. Rulcová J. Význam kombinované hormonální antikoncepce u hyperandrogenních stavů. Arch Dermatology-CZ, 2004; 4, 2: 106-107.
    11. Thiboutot D. Hormones and acne: pathophysiology, clinical evaluation and therapies. (Review). Seminars in Cutaneous Medicine et Surgery 2001; 20, 3: 144-153. Go to original source... Go to PubMed...
    12. Shaw JC. Hormonal therapy in dermatology. Dermatol Clin. 2001; 19(1): 169-178. Review. Go to original source... Go to PubMed...
    13. Křepelka P. Kombinovaná hormonální kontracepce v léčbě akné. Akné report 2004; 2: 6.
    14. Vohradníková O. Terapie akné dospělých žen. Trendy v medicíně 2000; 2, 4: 27-28.
    15. Cibula D, Hill M, Vohradníková O, et al. The role of androgens in determining acne severity in adult women. Br J Dermatol, 143, 2000: 399-404. Go to original source... Go to PubMed...
    16. Rabe T, Kowald A, et al. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol. 2000; 14 (4): 223-230. Go to original source... Go to PubMed...
    17. Thiboutot D, Chen W. Update and future of hormonal therapy in acne. Dermatology 2003; 206 (1): 57-67. Review. Go to original source... Go to PubMed...
    18. Rulcová J. Celkově aplikovaná léčba. Referátorový výběr z Dermatovenerologie, Acne vulgaris, 2004; Speciál - II: 16-24.
    19. Rabe T, Grunwald K, Feldmann K, Runnebaum B. Treatment of hyperandrogenism in women. Gynecol Endocrinol 1996; 10 (Suppl. 3): 1-44. Go to original source...
    20. Rulcová J. Výsledky léčby Diane(R) 35 u pacientek s acne vulgaris. Praktická gynekologie 2000; 1: 14-17.
    21. Haider A, Shaw JC. Léčba acne vulgaris. JAMA-CS 2004; 12, 12: 807-817. Go to original source... Go to PubMed...
    22. Schramm G, Steffens D. Contraceptive Efficacy and Tolerability of Chlormadinone Acetate 2mg/Ethinylestradiol 0.03 mg (Belara(R)). Results of a Post-Marketing Surveillance Study. Clin Drug Invest 2002; 22, (4): 221-230. Go to original source...
    23. Raudrant D, Rabe T. Progestogens with Antiandrogenic Properties. Drugs 2003; 63 (5): 463-492. Go to original source... Go to PubMed...
    24. Plewig G, Kligman AM. Acne and Rosacea. 3 rd Completely Revised and Enlarged Edition. Springer-Verlag Berlin Heidelberg 2000: 683-689. Go to original source...
    25. Cibula D. Přípravek kombinované hormonální kontracepce s novým gestagenem - dienogestem. Moderní gynekologie a porodnictví, 11, 1. Suppl. A, 2002: 107-108.
    26. Zimmermann T, Wisser KH, Dietrich H. Účinky perorálního kontraceptiva obsahujícího dienogest Jeanine(R), Valette(R) na kůži a vlasy: výsledky postmarketingové studie. Moderní gynekologie a porodnictví 2002; 11, 1 (Suppl. A): 125-132.
    27. Šimaljaková M, Rasochová E, Kissová A. Význam Jeanine(R) v dermatológii. Derma 2003; III, 1: 5-8.
    28. Leyden J, Shalita A, Hordinsky M, et al. Efficacy of a low-dose contraceptive containing 20 ug of ethinyl estradiol and 100 ug of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial. J Am Acad Dermatol. 2002; 47: 399-409. Go to original source... Go to PubMed...
    29. Thiboutot D, Archer DF, Lemay A, et al. A randomized, controlled trial of a low-dose contraceptive containing 20 ug of ethinyl estradiol and 100 ug of levonorgestrel for acne treatment. Fertil and Steril 2001; 76: 461-468. Go to original source... Go to PubMed...
    30. Paseka J, Unzeitig V, Hořejší V, a kol. Klinická studie s třífázovým antikoncepčním přípravkem (norgestimát 180/ 215/250 ug + ethinylestradiol 35 ug) v populaci českých žen. Čes. Gynek 1999; 4: 246-254.
    31. Cibula D, Paseka J, Unzeitig V, a kol. Predikce vlivu třífázového antikoncepčního přípravku s norgestimátem na akné. Čes. Gynek 2000; 65: 79-82.
    32. Lucky W, Henderson T, Olson W, et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J. Am. Acad. Dermatol 1997; 37, 5: 746-754. Go to original source... Go to PubMed...
    33. Rulcová J, Chroust K. Účinnost a snášenlivost třífázového antikoncepčního přípravku s norgestimátem (Pramino(R), Janssen-Cilag) v léčbě acne vulgaris. Derma 3. tisícročia 2002; 2: 10-13.
    34. Redmond PG, Olson WH, Lippman JS, et al. Norgestimate and Ethinyl Estradiol in the Treatment of Acne Vulgaris: A randomized, Placebo-Controlled Trial. Obstet Gynecol 1997; 89: 615-622. Go to original source... Go to PubMed...
    35. Runnebaum B, Gruwald K, Rabe T. The efficacy and tolerability of norgestimate/ethinyl estradiol (250 ug of norgestimate/35 ug of ethinyl estradiol): Results of an open, multicenter study of 59, 701 women. Am. J. Obstet Gynecol 1992; 166: 1963-1968. Go to original source... Go to PubMed...
    36. Muhn P, Krattenmacher R, Beier S, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Contraception 1995; 51: 99-110. Go to original source... Go to PubMed...
    37. Produktová monografie. Yadine. Schering AG, Germany. Yadine(R), drospirenon 3,00 mg + ethinylestradiol 0,03mg. Produktová monografie, 2000: 3-45.
    38. Zelenková H. Možnosti ovplyvnenia acne vulgaris prípravkom a obsahom desogestrelu a ethinylestradiolu. Derma 3. tisícročia 2003; 3: 13-16.
    39. Collins D. Selectivity information on Desogestrel. Am. J. Obstet. Gynecol 1993; 168: 1010-1016. Go to original source... Go to PubMed...
    40. Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet 2003; 362: 185-191. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.